The US Pharmaceutical Contract Manufacturing Market was valued at $35360 Million in 2025 and projected to reach to $50100 Million by 2030, representing a compound annual growth rate of 7.2%. The US pharmaceutical contract manufacturing market is positioned for sustained growth driven by increasing outsourcing adoption among mid-sized and emerging biopharmaceutical companies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US pharmaceutical contract manufacturing market is valued at $35.36 billion in 2025 and is projected to reach $50.1 billion by 2030, representing a robust 7.2% CAGR. This growth trajectory reflects strong demand from domestic biopharmaceutical companies seeking specialized manufacturing capabilities.
The US benefits from FDA's established regulatory frameworks and Good Manufacturing Practice (GMP) standards that attract global pharmaceutical companies to outsource production domestically. This regulatory certainty drives premium pricing and sustained market expansion across the region.
Major biopharmaceutical innovation clusters in California, Massachusetts, and New Jersey create concentrated demand for contract manufacturing services. These regions house leading drug developers requiring specialized CDMO capabilities for complex biologics and small molecules.
The US market represents a mature segment with established players and ongoing consolidation trends. Strategic M&A activity among contract manufacturers is reshaping competitive dynamics and expanding service portfolios to capture growing outsourcing demand.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | DRUG DEVELOPMENT SERVICES (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 8.2% from 2025 to 2030 |
| Largest Segment | PHARMACEUTICAL MANUFACTURING SERVICES (Service) |
| Market Size Base Year (Billions) | ~USD 210.35 (2025) |
| Revenue Forecast (Billions) | ~USD 311.95 (2030) |
| Segments Covered | Service, Type, Molecule, End User |
4 segment dimensions are covered across the global market.
The US pharmaceutical contract manufacturing market is valued at $35.36 billion in 2025.
The US pharmaceutical contract manufacturing market is projected to reach $50.1 billion by 2030.
The US market is expected to grow at a compound annual growth rate of 7.2% from 2025 to 2030.
Key drivers include rising demand for specialized manufacturing capabilities such as biologics and complex small-molecule production, consolidation among service providers, and increased outsourcing by pharmaceutical companies seeking to optimize efficiency.
The US benefits from advanced regulatory frameworks, established infrastructure, concentration of biopharmaceutical innovation hubs, and strong competition for capacity in sterile injectable and fill-finish services.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global pharmaceutical contract manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract manufacturing market. The secondary sources used for this study include Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Pharma Times, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information, Eurostat, Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), World Journal of Pharmaceutical Sciences, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Following an initial assessment of the global pharmaceutical contract manufacturing market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the pharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Pharmaceutical contract manufacturing organizations (CMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CMOs offer manufacturing services for active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Different aspects of contract manufacturing, such as drug development & manufacturing, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this report.
Full forecast, segment splits, and company analysis for all Pharmaceutical Contract Manufacturing Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report